Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation.
Roy V et al. Blood Cancer J. 2015 Mar 20;5:e294. doi: 10.1038/bcj.2015.23.

Phase III trial of bortezomib, cyclophosphamide, dexamethasone (VCD) versus bortezomib, doxorubicin, dexamethasone (PAd) in newly-diagnosed myeloma.
Mai EK et al. Leukemia. 2015 Mar 19. doi: 10.1038/leu.2015.80. [Epub ahead of print].

Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma.
Sahebi F et al. Bone Marrow Transplant. 2015 Mar 23. doi: 10.1038/bmt.2015.45. [Epub ahead of print].

Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myelomaand renal impairment.
Zhou DB et al. Int J Hematol. 2015 Mar 10. [Epub ahead of print].

Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma.
Kusumoto S et al. Int J Hematol. 2015 Mar 7. [Epub ahead of print].

Phase I/II trial of lenalidomide and high dose melphalan with autologous stem cell transplantation for relapsed myeloma.
Shah N et al. Leukemia. 2015 Feb 27. doi: 10.1038/leu.2015.54. [Epub ahead of print].

Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.
Breitkreutz I et al. Hematol Oncol. 2015 Mar 18. doi: 10.1002/hon.2199. [Epub ahead of print].